

# Biofilm (colonisation of microorganisms) formation in different types of nasogastric tubes used in preterm neonates

<b>Submission date</b> 04/03/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 11/11/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 11/11/2021	<b>Condition category</b> Neonatal Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Preterm babies in neonatal units require a number of procedures and equipment for their care including incubators, ventilators, monitoring devices, various tubes and catheters. Nasogastric (NG) tube insertion is one of the most common interventions undertaken in neonatal units. Depending upon the gestational age of the baby, the duration of NG tube placement is variable ranging from very short term (a few days) to long term (a few months).

Although the NG tube is needed and has been used for a long time in preterm babies in neonatal units, its effects on feed-related complications and microbiological associations are not thoroughly studied. The risk of infection is always taken seriously in the neonatal units and a number of strategies are put in place to prevent this. It is beyond doubt that immune-deficient preterm newborns in an intensive care setting are prone to colonisation (bacteria present and growing but not causing an infection) with a number of organisms, some of which can easily turn infective under favourable conditions for their growth.

In relation to the NG tubes, there is now enough evidence to suggest that microorganisms can grow in the form of a biofilm. The biofilm, in simpler terms, is a collection of organisms (bacteria, viruses and fungi) that can stick or grow on a variety of surfaces. Examples of biofilms include dental plaque and pond scum. A biofilm generally starts when free-floating bacteria come in contact with a suitable surface and can vary from very few layers of cells to a well-formed bacterial colony. It may potentially be a source of infection in preterm infants.

One of the most commonly used designs of NG tubes in neonates has a closed tip. There are new types of NG tubes that are now available which have an open tip and are being commonly used now. There have not been any controlled studies to suggest the advantage of one type of design over the other in the preterm population. The researchers' standard practice over the years had been to use the closed tip NG tube. The open-end tube has recently been introduced in clinical practice although not used very often.

The aim of this study is to analyse any differences in biofilm formation (bacterial colonisation) when different types of tubes are used. The researchers will also study its effects on certain feed-related complications, for example, intolerances, and the acidity of the stomach.

Who can participate?

Stable preterm infants born between 27+0 to 31+6 weeks gestation

What does the study involve?

As part of this study, infants are randomly allocated to one of two different types of NG tubes, one has a closed tip (current practice) and the other has an open tip (became available only recently). Both the tubes are safe to use. Having a plastic tube in any body cavity might promote the growth of bacteria and with this study, the researchers want to find out whether there are any differences in the way the bacteria grow depending upon which tube is used.

What are the possible benefits or risks of participating?

The researchers do not see any risk of participating as the care received by the baby will not be affected. The perceived benefit is that biofilm formation might be reduced in the open tip design although the researchers do not know that as yet.

Where is the study run from?

The James Cook University Hospital (UK)

When is the study starting and how long is it expected to run for?

March 2021 to December 2022

Who is funding the study?

The James Cook University Hospital (UK), also received funding from a commercial company (Avanos)

Who is the main contact?

Dr Shalabh Garg

s.garg@nhs.net

## Contact information

### Type(s)

Scientific

### Contact name

Dr Shalabh Garg

### ORCID ID

<http://orcid.org/0000-0001-5572-520X>

### Contact details

Consultant Neonatologist

James Cook University Hospital

Marton Road

Middlesbrough

United Kingdom

TS4 3BW

+44 (0)1642854834

s.garg@nhs.net

# Additional identifiers

## EudraCT/CTIS number

Nil known

## IRAS number

294415

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

CPMS 49886, IRAS 294415

# Study information

## Scientific Title

Randomised controlled trial to study the differences in the biofilm formation in occluded and open-tip nasogastric tubes in preterm neonates

## Acronym

BOON

## Study objectives

The insertion of nasogastric (NG) tubes in preterm neonates is one of the commonest procedures undertaken during their NICU stay. There are few observational studies to suggest that these NG tubes can get colonised with microorganisms (biofilm). Although the differences in the biofilm formation on the different type of NG tubes are not studied in preterm neonates. The two types of NG tubes available to be used in preterm babies are the open tip or the closed tip at the distal end.

It is hypothesized that there will be a significant reduction in the biofilm formation in the open tip design of the NG tube which will be studied in a randomised controlled trial in this study on preterm babies (27 to 31 weeks gestation)

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomized controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Prevention

**Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet

**Health condition(s) or problem(s) studied**

Biofilm formation in preterm neonates

**Interventions**

Randomisation:

Minimisation using gestation (<30+0 weeks) yes/no. Twins and triplets will be allocated to the same study arm. Secured, password-protected web-based randomisation using a minimisation algorithm (<https://www.sealedenvelope.com> or similar).

Interventions:

1. Commonly used closed-ended nasogastric tube (control group)
2. The newly available open-ended nasogastric tube (Intervention group)

Study duration:

7 days or less from the point of randomisation; some babies will be in the study for longer if the NG tube dislodged or had to be taken out due to clinical reasons before 4 days (presumed time period for possible biofilm formation based on the preliminary data).

**Intervention Type**

Device

**Phase**

Not Applicable

**Primary outcome measure**

1. Incidence of biofilm formation assessed by microbiological assay for each type of NG tube after it is removed
2. Colony forming units of the bacteria grown during microbiological culture for each type of NG tube after it is removed

**Secondary outcome measures**

1. Average gastric pH measured using [method] throughout the duration of NG tube in situ - between 4 to 7 days
2. The incidence of feed intolerance (nil by mouth, bilious aspirates, vomiting), measured using [method] for the duration of NG tube in situ - between 4 to 7 days

**Overall study start date**

01/03/2021

**Completion date**

31/12/2022

# Eligibility

## Key inclusion criteria

1. Stable preterm infants born between 27+0 to 31+6 weeks gestation
2. Tolerating at least 48 ml/kg/day of enteral milk feed (chosen due to local preterm feeding protocol)
3. The clinical need for nasogastric tube insertion
4. Written informed consent from parents

## Participant type(s)

Patient

## Age group

Neonate

## Sex

Both

## Target number of participants

100

## Key exclusion criteria

1. No informed consent available
2. Not tolerating  $\geq 50$  ml/kg/day of enteral feeds
3. Known congenital anomaly or surgical condition of the GI tract

## Date of first enrolment

01/06/2021

## Date of final enrolment

31/12/2021

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

**The James Cook University Hospital**

South Tees Hospitals NHS Foundation Trust

Neonatal Unit

Marton Road

Middlesbrough

United Kingdom

TS4 3BW

# Sponsor information

## Organisation

South Tees Hospitals NHS Foundation Trust

## Sponsor details

The James Cook University Hospital  
Marton Road  
Middlesbrough  
England  
United Kingdom  
TS4 3BW  
+44 (0)1642850850  
joe.millar@nhs.net

## Sponsor type

Hospital/treatment centre

## Website

<https://www.southtees.nhs.uk/>

## ROR

<https://ror.org/02js17r36>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

James Cook Hospital

## Funder Name

Avanos

# Results and Publications

## Publication and dissemination plan

1. The protocol, parent information sheet and consent form can be made available in due course. The protocol is not yet published or available online.

2. After the data analysis, the study results will be presented at national and international conferences. The manuscript will be written and submitted for publication in peer-reviewed journals.

**Intention to publish date**

31/12/2023

**Individual participant data (IPD) sharing plan**

In view of the Trust's governance guidance, the patient data will be kept confidential and only anonymous analysis can be shared. The data will be kept secure only on the hospital computers which are only to be used by authorised professionals.

**IPD sharing plan summary**

Not expected to be made available